EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY-NC 4.0

First‐line immunotherapy of metastatic renal cell carcinoma: an updated network meta‐analysis including triplet therapy

Takafumi Yanagisawa iD, Tatsushi Kawada iD, Kensuke Bekku iD, Ekaterina Laukhtina iD, Pawel Rajwa iD, Markus von Deimling, Marcin Chlosta, Fahad Quhal, Benjamin Pradere, Pierre I Karakiewicz, Keiichiro Mori iD, Takahiro Kimura und 2 weitere

BJU International · 2024

DOI: 10.1111/bju.16336 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift BJU International, 2024. Verfasst von Takafumi Yanagisawa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Anilides, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the differential efficacy of first‐line immune checkpoint inhibitor (ICI)‐based combined therapies among patients with intermediate‐ and poor‐risk metastatic renal cell carcinoma (mRCC), as recently, the efficacy of triplet therapy comprising nivolumab plus ipilimumab plus cabozantinib has been published. Patients and Methods Three databases were searched in December 2022 for randomised controlled trials (RCTs) analysing oncological outcomes in patients with mRCC treated with first‐line ICI‐based combined therapies. We performed network meta‐analysis (NMA) to compare the outcomes, including progression‐free survival (PFS) and objective response rates (ORRs), in patients with intermediate‐ and poor‐risk mRCC; we also assessed treatment‐related adverse events.

Results

Overall, seven RCTs were included in the meta‐analyses and NMAs. Treatment ranking analysis revealed that pembrolizumab + lenvatinib (99%) had the highest likelihood of improved PFS, followed by nivolumab + cabozantinib (79%), and nivolumab + ipilimumab + cabozantinib (77%). Notably, compared to nivolumab + cabozantinib, adding ipilimumab to nivolumab + cabozantinib did not improve PFS (hazard ratio 1.02, 95% confidence interval 0.72–1.43). Regarding ORRs, treatment ranking analysis also revealed that pembrolizumab + lenvatinib had the highest likelihood of providing better ORRs (99.7%). The likelihoods of improved PFS and ORRs of pembrolizumab + lenvatinib were true in both International Metastatic RCC Database Consortium (IMDC) risk groups.

Conclusions

Our analyses confirmed the robust efficacy of pembrolizumab + lenvatinib as first‐line treatment for patients with intermediate or poor IMDC risk mRCC. Triplet therapy did not result in superior efficacy. Considering both toxicity and the lack of mature overall survival data, triplet therapy should only be considered in selected patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnilidesAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellImmune Checkpoint InhibitorsKidney NeoplasmsHumansAntibodies, Monoclonal, HumanizedImmunotherapyIpilimumabNivolumabPhenylurea CompoundsProgression-Free SurvivalPyridinesQuinolinesRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

cabozantinibimmune checkpoint inhibitorsipilimumabmetastasisnivolumabrenal cell carcinoma

Substanzen

AnilidesAntibodies, Monoclonal, HumanizedcabozantinibImmune Checkpoint InhibitorsIpilimumablenvatinibNivolumabpembrolizumabPhenylurea CompoundsPyridines

Autor:innen und Institutionen

  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Department of Urology, Medical University of Silesia, Zabrze, Poland.
  • Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Clinic of Urology and Urological Oncology, Jagiellonian University, Krakow, Poland.

ORCID-Profile: Takafumi Yanagisawa, Tatsushi Kawada, Kensuke Bekku, Ekaterina Laukhtina, Pawel Rajwa, Keiichiro Mori

Zitieren

APA

Yanagisawa, T., Kawada, T., Bekku, K., Laukhtina, E., Rajwa, P., von Deimling, M., Chlosta, M., Quhal, F., Pradere, B., Karakiewicz, P. I., Mori, K., Kimura, T., Shariat, S. F., & Schmidinger, M. (2024). First‐line immunotherapy of metastatic renal cell carcinoma: an updated network meta‐analysis including triplet therapy. BJU International. https://doi.org/10.1111/bju.16336

Vancouver

Yanagisawa T, Kawada T, Bekku K, Laukhtina E, Rajwa P, von Deimling M, et al. First‐line immunotherapy of metastatic renal cell carcinoma: an updated network meta‐analysis including triplet therapy. BJU International. 2024. doi:10.1111/bju.16336

BibTeX
@article{Yanagisawa2024,
  author = {Yanagisawa, Takafumi and Kawada, Tatsushi and Bekku, Kensuke and Laukhtina, Ekaterina and Rajwa, Pawel and von Deimling, Markus and Chlosta, Marcin and Quhal, Fahad and Pradere, Benjamin and Karakiewicz, Pierre I and Mori, Keiichiro and Kimura, Takahiro and Shariat, Shahrokh F and Schmidinger, Manuela},
  title = {First‐line immunotherapy of metastatic renal cell carcinoma: an updated network meta‐analysis including triplet therapy},
  journal = {BJU International},
  year = {2024},
  doi = {10.1111/bju.16336}
}
Kostenlos starten →